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Abstract
Staphylococcus aureus isolates from developed countries have been extensively analyzed with respect to their virulence patterns and clonal
relatedness but there is only sparse information on the molecular diversity of S. aureus isolates from Africa. In particular, little is known
about S. aureus isolates from asymptomatic carriers compared with isolates causing infections. From 2008 to 2010, we prospectively col-
lected S. aureus isolates from asymptomatic carriers and infections in Lambare´ne´, Gabon, Central Africa. For these isolates, we determined
major virulence factors, and performed multilocus sequence typing (MLST) and spa typing. Among 163 S. aureus isolates from asymptomatic
carriers, we found the MLST clonal complexes (CCs) 5, 6, 7, 8, 9, 15, 25, 30, 45, 88, 101, 121 and 152; 3.7% were methicillin-resistant
(MRSA). The clinical isolates were associated with CCs 5, 8, 9, 15, 88, 121 and 152; 11% were MRSA. Sequence types 1 and 88 were signiﬁ-
cantly associated with infection and sequence type 508 was associated with carriage. Remarkably, there was a high prevalence of Panton–
Valentine leukocidin (PVL) -encoding genes both in disease-related isolates (57.4%) and in carrier isolates (40.5%). We found differences in
the clonal structure and virulence pattern of Gabonese S. aureus isolates from asymptomatic carriers and infections. Of note, S. aureus iso-
lates from Gabon show a very high prevalence of PVL-encoding genes, which exceeds the rates observed for developed countries.
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Introduction
Staphylococcus aureus is a human pathogen causing a variety
of diseases ranging from superﬁcial skin and soft-tissue infec-
tions to life-threatening conditions such as necrotizing pneu-
monia [1,2]. The anterior nares are the main primary
ecological reservoir of S. aureus in humans and about 25%
of the world’s population are persistently colonized [2,3].
Interestingly, nasal colonization was identiﬁed as a major risk
factor for subsequent S. aureus infection [4]. However, the
clonal lineages of S. aureus isolates and the distribution of vir-
ulence factors might differ between isolates derived from
asymptomatic carriers and from infections as well as
between different geographic regions [5]. For instance, car-
rier isolates in industrialized countries show a higher preva-
lence of genes of the enterotoxin gene cluster (egc), seg, sei,
sem, sen and seo compared with disease-associated isolates
[6–8]. In contrast to egc, the ﬁxed gene combination sed and
sej and the leukocidin lukE-lukD genes are more prevalent in
clinical isolates than in carrier isolates [8–10]. Leukocidins
are bi-component exoproteins forming pores in cellular
membranes. The Panton-Valentine leukocidin (PVL), consist-
ing of the two subunits LukS-PV and LukF-PV, is a potent
cytocidal toxin that causes dermonecrosis and lysis of human
granulocytes and enhances the adherence of S. aureus to
extracellular matrix [11].
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Whereas the differences between S. aureus carrier and
clinical isolates from developed countries have been exten-
sively investigated, data from African countries are limited
and mostly available for S. aureus isolates derived from infec-
tion. A few studies have indicated that African S. aureus iso-
lates have completely different clonal structure and virulence
patterns compared with isolates from industrialized coun-
tries: 25% of Malian carrier isolates belonged to the PVL-
positive sequence type (ST) 152 as determined by multilocus
sequence typing (MLST) [12], 42.7% of Nigerian isolates and
72% of methicillin-resistant S. aureus (MRSA) isolates from
Algeria were PVL-positive [13,14], 57% of clinical S. aureus
isolates in an African multi-centre study carried genes which
encoded PVL [15].
So far, isolates from asymptomatic carriers and infections
from the same African region have not been compared to
address the question of whether there are differences in the
distribution of clonal lineages and virulence factors between
these two groups.
Therefore, this study aims to compare carrier-related and
infection-related isolates from the same region in Gabon
with respect to important virulence markers and genotypes
to elucidate differences between carrier and disease isolates.
The data will be used to assess the risk for certain toxin-
mediated S. aureus infections such as toxic shock syndrome,
diarrhoea or skin and soft-tissue infections associated with
PVL.
Materials and Methods
Study population
Within the German–African network on staphylococci and
staphylococcal diseases (DFG PAK 296), 552 participants liv-
ing in Gabon, in the province ‘Moyen-Ogooue´’ were
screened for carriage of S. aureus from July 2008 to May
2010. Among these people, 163 were asymptomatic carriers
of S. aureus. Swabs were taken from the anterior nares, the
axilla and the groin. Only one isolate per patient was
included in this study. If participants were colonized at differ-
ent body sites, we gave priority to nasal isolates over axil-
lary/inguinal isolates and axillary isolates over inguinal
isolates. The carrier group comprised inpatients (n = 53),
outpatients (n = 13), hospital personnel (n = 33) and partici-
pants without previous health-care contact (n = 64). The
mean age (± SD) ranged from 25.8 years (± 20.0) in partici-
pants without previous health-care contact to 40.3 years
(± 7.3) in hospital personnel. Males and females were equally
distributed in all carrier groups except for the hospital per-
sonnel, who had a higher percentage of females (78.8%).
The S. aureus isolates from infection were collected in
the routine laboratory of the Albert Schweitzer Hospital,
Lambare´ne´, Gabon, from January 2009 to May 2010
(n = 54).
Written informed consent was obtained from all asymp-
tomatic carriers before recruitment. Ethical approval for this
study was obtained from the ‘Comite´ d’E´thique Re´gional
Inde´pendant de Lambare´ne´’ (CERIL), Lambare´ne´, Gabon.
Bacterial isolates
Carriage and disease isolates were cultured on sheep blood
agar plates and presumptive S. aureus colonies were identi-
ﬁed by a positive catalase reaction, latex agglutination test
(Pastorex Staph-Plus, Bio-Rad Laboratories, Marnes-la-Co-
quette, France) and rabbit coagulase test (Becton, Dickinson
and Company, Erembodegem, Belgium). Species conﬁrmation
of S. aureus and detection of the mecA gene encoding
methicillin resistance were performed for all isolates [16].
For one nuc-negative, coagulase-positive isolate, further
species conﬁrmation was carried out by sequencing the ribo-
somal 16S rRNA gene [17].
Virulence factors and capsular polysaccharides
Genes encoding PVL (lukS-PV/lukF-PV), toxic shock syn-
drome toxin (tst), enterotoxins (sea, seb, sec, sed, see, seg,
seh, sei, sej), exfoliative toxins (eta, etb, etd), members of the
epidermal cell differentiation inhibitor (edin-A, edin-B, edin-C)
and capsular polysaccharide type 5 and 8 were detected as
published elsewhere [8,9,18,19].
Genotyping
Typing of the hypervariable region of protein A (spa typing)
was performed as described previously [20]. We performed
MLST exemplarily for each spa type [21]. All STs of our data
set were compared with all allelic proﬁles of the MLST data-
base using eBURST (version 3, http://eburst.mlst.net, 18
March 2011). We used the stringent group deﬁnition of a
minimum of six out of seven shared alleles to assign the STs
of this study to known clonal complexes.
Statistics
Genotypes and virulence factors of carrier and clinical S. aur-
eus isolates were compared using the software ‘R’ (http://
cran.r-project.org, Version: 2.10.1) and package EPICALC. Pear-
son’s chi-square test or Fisher’s exact test were used when
appropriate to analyze the proportions of categorical data.
The strength of association was calculated using OR and the
95% CI. The signiﬁcance level was set at 5%. Simpson’s index
of diversity was calculated to assess diversity of genotypes
within groups.
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Results
Study population
Fifty-four S. aureus isolates from clinical samples were com-
pared with 163 S. aureus carrier isolates collected in the
Lambare´ne´ region in Gabon. Clinical isolates were recovered
from patients with wound infection (n = 21), bacteraemia
(n = 11), abscesses (n = 10), otitis (n = 4), adenitis without
speciﬁcation (n = 3), pyomyositis (n = 2), cerebrospinal infec-
tion (n = 1), vaginitis (n = 1), and phlegmon (n = 1). The prev-
alence of MRSA among clinical isolates was 11.1% (n = 6).
The isolates from asymptomatic carriers were obtained
from the nose (n = 120), the axilla (n = 26) and the groin
(n = 12). The carriage site of ﬁve carrier isolates was not
recorded. Of all carrier isolates, 3.7% (n = 6) were positive
for mecA.
Comparison of virulence factors
The virulence factors of clinical and carrier S. aureus isolates
are shown in Table 1. Carrier isolates more frequently
encoded at least one of the pyrogenic toxin superantigens
(71.8% vs 64.8%, OR 0.73, 95% CI 0.36–1.49, p 0.33) or one
of the exfoliative toxins tested (7.98% vs 3.7%, OR 0.45, 95%
CI 0.05–2.07, p 0.283). Clinical isolates were signiﬁcantly
associated with the presence of PVL-encoding genes (OR
1.97, 95% CI 1.01–3.89, p 0.03), seh (OR 2.96, 95% CI 0.94–
9.2, p 0.028) and edin-A (OR 9.41, 95% CI 0.74–501.7,
p 0.049). The gene see was not detected in either carrier or
clinical isolates. The ﬁxed gene combination seg-sei was
always co-detected in both clinical and carrier isolates
(Table 1). In contrast, the linked gene loci sed-sej were only
present in one carrier isolate. Three carrier isolates encoded
sej alone. The distribution of capsular polysaccharide 5 and 8
(CP5 and CP8) is shown in Table 1. Except for one carrier
isolate (ST8), all MRSA isolates were PVL-negative.
Disease-association of PVL
As the possession of PVL-encoding genes was signiﬁcantly
associated with isolates from infection, we analyzed the pres-
ence of PVL-encoding genes among isolates from different
entities of infection (Table 2). We detected a signiﬁcant asso-
ciation of PVL-encoding genes with isolates derived from
abscesses (OR ¥, 95% CI 2.18–¥, p 0.003, Table 2). The STs
related to abscesses were ST1 (n = 3), ST15 (n = 3), ST88
(n = 1), ST152 (n = 1) and ST1746 (n = 2).
Genetic background
The 217 isolates exhibited 67 different spa types (Table 3).
In carrier isolates, t084 (33.7%) was the most prevalent, fol-
TABLE 1. Comparison of toxin genes in Staphylococcus aureus isolates from carriers and infected sites
Toxin gene
No. (%) of positive isolates
ORa (95% CI) pb
Carriage Disease Total
No. % No. % No. %
lukF-PV/lukS-PV 66 40.5 31 57.4 97 44.7 1.97 (1.01–3.89) 0.03
tst 16 9.82 3 5.56 19 8.76 0.54 (0.10–2.01) 0.42
sea 56 34.4 16 29.6 72 33.2 0.81 (0.38–1.63) 0.52
seb 16 9.82 1 1.85 17 7.83 0.17 (0–1.18) 0.078
sec 22 13.5 4 7.4 26 12.0 0.51 (0.12–1.62) 0.334
sed 1 0.61 0 0 1 0.46 0 (0–117.51) 1
seg 54 33.1 12 22.2 66 30.4 0.58 (0.26–1.23) 0.131
seh 9 5.52 8 14.8 17 7.83 2.96 (0.94–9.20) 0.028
sei 54 33.1 12 22.2 66 30.4 0.58 (0.26–1.23) 0.131
sej 4 2.45 0 0 4 1.84 0 (0–4.59) 0.574
eta 9 5.52 2 3.7 11 5.07 0.66 (0.07–3.33) 0.735
etb 1 0.61 0 0 1 0.46 0 (0–117.51) 1
etd 4 2.45 0 0 4 1.84 0 (0–4.59) 0.574
edin-A 1 0.61 3 5.56 4 1.84 9.41 (0.74–501.70) 0.049
edin-B 9 5.52 3 5.56 12 5.53 1.01 (0.17–4.24) 1
edin-C 1 0.61 0 0 1 0.46 0 (0–117.51) 1
cap5 42 25.8 14 25.9 56 25.8 1.01 (0.46–2.12) 0.98
cap8 119 73 40 74.1 159 73.3 1.06 (0.50–2.31) 0.87
aOR = odds ratio with 95% conﬁdence interval (CI).
bBoldface p-values indicate signiﬁcant association between the respective virulence factor and disease.
TABLE 2. Distribution of Panton–Valentine leukocidin
(PVL) -encoding genes among Staphylococcus aureus isolates
from clinical infection
Specimen source
No. PVL-positive
isolates (%) ORa (95% CI) p-value
Abscess (n = 10) 10 (100) ¥ (2.18–¥) 0.003
Wound (n = 21) 12 (57.1) 0.98 (0.28–3.45) 0.975
Blood (n = 11) 5 (54.5) 0.57 (0.12–2.66) 0.402
Otherb (n = 12) 4 (33.3) 0.28 (0.05–1.28) 0.096
aOR = odds ratio with 95% conﬁdence interval (CI).
bincluding otitis (n = 4), adenitis without speciﬁcation (n = 3), pyomyositis
(n = 2), cerebrospinal infection (n = 1),vaginitis (n = 1), phlegmon (n = 1).
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lowed by t355 (5.5%) and t279 (4.3%). Similarly, t084 (25.9%)
was the most prevalent in clinical isolates, followed by t355
(11.1%), t2723 and t4195 (5.6% each). Multilocus sequence
typing resulted in 24 different STs in isolates from carriage
and disease (Table 3). We detected new STs, designated
ST1745 and ST1746. A third new ST was only found once in
a carrier isolate which was nuc-negative (ST1822, Table 3).
Most STs were equally distributed among both groups
(Table 3). Only ST1 and ST88 were signiﬁcantly associated
with clinical infection (OR 3.35, 95% CI 1.03–10.86, p 0.016
and OR 5.18, 95% CI 1.55–18.7, p 0.001, Table 3, Fig. 1). In
contrast, ST508 was associated with carriage (OR 0, 95% CI
0–0.87, p 0.024). Overall, seven of the thirteen CCs found
among carrier isolates were also found in S. aureus derived
from infection (CCs 5, 15, 8, 9, 88, 121, 152). Except for
CC5, these CCs were also the only PVL-positive CCs com-
prising the following PVL-positive STs (percentage of all PVL-
positive S. aureus isolates): ST1 (10.31%), ST8 (1.03%), ST9
(1.03%), ST15 (60.82%), ST88 (2.06%), ST120 (1.03%), ST121
(2.06%), ST152 (15.46%), ST188 (1.03%) and ST1746 (5.15%).
When applying the Simpson’s index of diversity, STs of
clinical samples were more diverse than STs of the carrier
TABLE 3. Distribution of multilocus sequence typing clonal complexes (CC), sequence types (ST), spa types, and Panton–Val-
entine leukocidin (PVL) encoding genes in clinical and carrier isolates from Gabon
CC ST spa type
Carriage (n = 163) Disease (n = 54)
PVL MRSA MSSA PVL MRSA MSSA
CC5 ST5 t002, t311, t653, t1215 0 1a 6 0 0 3
CC6 ST6 t304, t701 0 0 3 NA 0 0
CC7 ST7 t091 0 0 1 NA 0 0
CC8 ST8 t008, t121, t197, t1476 1 1b 5 0 0 3
ST72 t148 0 0 6 0 0 1
ST94 t024 NA 0 0 0 0 1
CC9 ST9 t1045, t2980, t4492 1 0 7 0 0 1
ST27 t099 0 0 1 NA 0 0
ST1292 t4236 0 0 1 NA 0 0
CC15 ST1 t127, t590, t693, t1407, t1931, t4832 3 0 8 7 0 8
ST15 t084, t085, t094, t254,t279, t326, t491,
t673, t774, t1711, t1877, t2636, t6240, t6318
46 0 75 13 0 17
ST188 t189 1 0 2 0 0 1
CC25 ST25 t148, t3772, t4680 0 0 4 NA 0 0
CC30 ST30 t017,t253 0 0 2 NA 0 0
CC45 ST45 t939 0 0 2 NA 0 0
ST508 t1113, t1510, t2784, t4576, t5575, t6241, t6243, 0 0 14 NA 0 0
ST1745 t6242 0 0 1 NA 0 0
CC88 ST88 t186, t729, t2253, t2723, t3202, t4195 1 4a 3 1 6a 3
CC101 ST101 t056 0 0 1 NA 0 0
CC121 ST120 t645 1 0 1 NA 0 0
ST121 t159 1 0 1 1 0 1
ST1746 t314, t940 1 0 2 3 0 3
CC152 ST152 t355, t4235 9 0 10 6 0 6
Singleton ST1822 t6331 0 0 1 NA 0 0
aPVL-negative.
bPVL-positive.
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.
FIG. 1. Proportions of sequence types (STs) in samples from carriage and disease. Almost one-half of the carrier isolates belong to ST15. Most
clinical isolates correspond to ST15, ST88 and ST1. Asterisks mark signiﬁcant associations of the respective ST with carriage or disease accord-
ing to Pearson’s chi-square test and Fisher’s exact test, respectively. *p <0.05, **p <0.005.
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isolates (0.84 vs 0.77). This is consistent with the ﬁnding that
the quotient of the number of STs and the number of iso-
lates was smaller in the group of carrier isolates (0.14 vs
0.22).
Discussion
We here present a ﬁrst characterization of a collection of
S. aureus isolates from clinical specimens and asymptomatic
carriers in Gabon. Compared with European countries, we
found high rates of PVL-positive isolates both in clinical and
carrier isolates. This is consistent with reports from other
African countries, where the prevalence of PVL ranged
between 17 and 74% in clinical isolates from Cameroon,
Nigeria, Madagascar, Morocco, Niger and Senegal [13,15]. In
our study, we detected a signiﬁcant association of PVL with
clinical infection (p 0.03, Table 1). This was strongest for iso-
lates recovered from abscesses as they were all PVL-positive
(Table 2). This association was also shown in other studies
[22,23]. However, it is not clear why African isolates have
such a high prevalence of PVL and if this high prevalence has
an impact on the incidence of disease. Further studies are
necessary to assess the impact of PVL isolates on developing
infection.
Other toxins, particularly the combination of different vir-
ulence factors, may also contribute to the incidence and
severity of S. aureus infection. We found a signiﬁcant associa-
tion of seh and edin-A with clinical isolates (Table 1). Other
studies comparing carrier isolates with clinical isolates from
blood cultures did not show this ﬁnding [8]. Genes encoding
other pyrogenic toxin superantigens were less prevalent
among the Gabonese isolates compared with carrier and
clinical isolates from industrialized countries: tst (8.8% vs
20.3–78%), sed (0.46% vs 7.0–13%), seg/sei (30.4% vs 55–
90%), and sej (1.8% vs 7.0–10%). In contrast, sea and eta
were more prevalent in our study (33.2% vs 15.9% and 5.1%
vs 1.2%) [8,24]. The absence of see is not surprising because
in European and American studies it was only detected in
0.5–3% of samples [8,24]. The enterotoxins sed and sej are
located on one plasmid linked by an intergenic region [8].
Notably, sed and sej have not been exclusively co-detected in
our study as three carrier isolates encoded sej alone. Such a
disconnection of sed and sej has already been reported but is
rare [25].
We found an unbalanced distribution of certain STs
among carrier and clinical isolates. Isolates belonging to ST1
and ST88 were signiﬁcantly associated with clinical infection
(Table 3). This is consistent with a recent report from China,
where ST88 among ST5 and ST7 was signiﬁcantly over-
represented in disease samples and was associated with an
increased virulence [26]. Isolates belonging to ST88 rarely
encode PVL but are related to community-associated MRSA
[27], whereas ST1 (USA400) is a pandemic PVL-positive
methicillin-susceptible S. aureus (MSSA) and MRSA clone
[27,28]. Both ST88 and ST1 have been described in clinical
isolates from different African countries [15,29].
In our study, ST508 was signiﬁcantly associated with car-
rier isolates and is rarely found in Africa among clinical
(2.6%) and carrier (1%) isolates [12,29].
Of note, ST15 was the predominant lineage in both dis-
ease-related and carriage isolates. This has also been
reported from Malian carrier isolates and is consistent with
a German study in which CC15 was the second most preva-
lent CC in asymptomatic carriers [12,30]. However, further
pan-African studies comparing carrier with clinical isolates
are warranted to verify the association of ST1 and ST88 with
infection and ST508 with carriage.
The PVL-positive isolates of our study were mainly sus-
ceptible to methicillin and belonged to STs that are consid-
ered to be pandemic (STs 1, 30, 121) [27]. The PVL-positive
STs 121 and 152 are more prevalent in Africa than on other
continents [12,27].
Out of six clinical and six carrier isolates, we only found
one PVL-positive MRSA. This is surprising, because STs of
pandemic PVL-positive MSSA were present in our study and
might function as a reservoir for PVL-positive MRSA as sug-
gested by others [27]. However, our study argues against an
intense inter-relation of PVL-positive MSSA and MRSA.
The STs of carrier isolates were less diverse compared
with those of clinical isolates (Simpson’s index of diversity
0.77 vs 0.84). This is surprising because one might expect
that only a selection of carrier isolates possesses the poten-
tial to become invasive [4]. We only found 12 different STs
among clinical isolates in contrast to 23 STs among carrier
isolates. The higher Simpsons’s index of diversity in clinical
isolates is based on the fact that it is calculated from the
total number of STs and the abundance of each ST. As the
carrier isolates had a smaller quotient of STs per isolate and
a strong dominance of ST15, they turned out to be less
diverse than the group of clinical isolates.
Limitations of our study are the small sample size of clini-
cal isolates. Furthermore, we only performed MLST exempl-
arily for each spa type. Although a high concordance of
MLST and spa typing results has been shown [20], one spa
type can correspond to several STs. Our strategy may there-
fore result in deviant proportions of STs within carriage and
disease isolates. However, we judge this deviation as a minor
limitation, as we recently performed MLST in all isolates
from another Gabonese population and did not detect
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homoplasy of spa types (Schaumburg F., Ko¨ck R., Friedrich
A.W., Soulanoudjingar S., von Eiff C., Issifou S., Kremsner
P.G., Herrmann M., Peters G. and Becher K., unpublished
data).
In conclusion, our study compares, for the ﬁrst time,
S. aureus isolates from infected patients and asymptomatic
carriers in a deﬁned Central African region and therefore
controls the geographical bias. It shows a high prevalence of
PVL in both groups, which was accentuated in clinical isolates
and abscesses in particular.
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